Advanced search
1 file | 2.00 MB

Advanced ovarian cancer: primary or interval debulking? : five categories of patients in view of the results of randomize trials and tumor biology : primary debulking surgery an interval debulking surgery for advanced ovarian cancer

(2016) ONCOLOGIST. 21(6). p.745-754
Author
Organization
Abstract
Background. Standard treatment of stage III and IV advanced ovarian cancer (AOC) consists of primary debulking surgery (PDS) followed by chemotherapy. Since the publication of the European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada trial, clinical practice has changed and many AOC patients are now treated with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery(IDS). The best option remains unclear. Ovarian cancer is a heterogenic disease. Should we use the diversity in biology of the tumor and patterns of tumor localization to better stratify patients between both approaches? Methods. This analysis was based on results of five phase III randomized controlled trials on PDS and IDS in AOC patients, three Cochrane reviews, and four meta-analyses. Results. There is still no evidence that NACT-IDS is superior to PDS. Clinical status, tumor biology, and chemosensitivity should be taken into account to individualize surgical approach. Nonserous (type 1) tumors with favorable prognosis are less chemosensitive, and omitting optimal PDS will lead to less favorable outcome. For patients with advanced serous ovarian cancer (type 2) associated with severe comorbidity or low performance status, NACT-IDS is the preferred option. Conclusion. We propose stratifying AOC patients into five categories according to patterns of tumor spread (reflecting the biologic behavior), response to chemotherapy, and prognosis to make a more rational decision between PDS and NACT-IDS.
Keywords
Stage III-IV, Debulking, Randomized trials, Ovarian cancer, type 1 and 2, Categories, PRIMARY CYTOREDUCTIVE SURGERY, GYNECOLOGIC-ONCOLOGY-GROUP, ADVANCED-STAGE OVARIAN, NEOADJUVANT CHEMOTHERAPY, SURGICAL CYTOREDUCTION, INDUCTION CHEMOTHERAPY, EXPLORATORY ANALYSIS, PROGNOSTIC-FACTOR, CARCINOMA, SURVIVAL

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 2.00 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Makar, Amin, Claes G Tropé, Philippe Tummers, Hannelore Denys, and Katrien Vandecasteele. 2016. “Advanced Ovarian Cancer: Primary or Interval Debulking? : Five Categories of Patients in View of the Results of Randomize Trials and Tumor Biology : Primary Debulking Surgery an Interval Debulking Surgery for Advanced Ovarian Cancer.” Oncologist 21 (6): 745–754.
APA
Makar, A., Tropé, C. G., Tummers, P., Denys, H., & Vandecasteele, K. (2016). Advanced ovarian cancer: primary or interval debulking? : five categories of patients in view of the results of randomize trials and tumor biology : primary debulking surgery an interval debulking surgery for advanced ovarian cancer. ONCOLOGIST, 21(6), 745–754.
Vancouver
1.
Makar A, Tropé CG, Tummers P, Denys H, Vandecasteele K. Advanced ovarian cancer: primary or interval debulking? : five categories of patients in view of the results of randomize trials and tumor biology : primary debulking surgery an interval debulking surgery for advanced ovarian cancer. ONCOLOGIST. 2016;21(6):745–54.
MLA
Makar, Amin, Claes G Tropé, Philippe Tummers, et al. “Advanced Ovarian Cancer: Primary or Interval Debulking? : Five Categories of Patients in View of the Results of Randomize Trials and Tumor Biology : Primary Debulking Surgery an Interval Debulking Surgery for Advanced Ovarian Cancer.” ONCOLOGIST 21.6 (2016): 745–754. Print.
@article{7190163,
  abstract     = {Background. Standard treatment of stage III and IV advanced ovarian cancer (AOC) consists of primary debulking surgery (PDS) followed by chemotherapy. Since the publication of the European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada trial, clinical practice has changed and many AOC patients are now treated with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery(IDS). The best option remains unclear. Ovarian cancer is a heterogenic disease. Should we use the diversity in biology of the tumor and patterns of tumor localization to better stratify patients between both approaches? 
Methods. This analysis was based on results of five phase III randomized controlled trials on PDS and IDS in AOC patients, three Cochrane reviews, and four meta-analyses. 
Results. There is still no evidence that NACT-IDS is superior to PDS. Clinical status, tumor biology, and chemosensitivity should be taken into account to individualize surgical approach. Nonserous (type 1) tumors with favorable prognosis are less chemosensitive, and omitting optimal PDS will lead to less favorable outcome. For patients with advanced serous ovarian cancer (type 2) associated with severe comorbidity or low performance status, NACT-IDS is the preferred option. 
Conclusion. We propose stratifying AOC patients into five categories according to patterns of tumor spread (reflecting the biologic behavior), response to chemotherapy, and prognosis to make a more rational decision between PDS and NACT-IDS.},
  author       = {Makar, Amin and Trop{\'e}, Claes G and Tummers, Philippe and Denys, Hannelore and Vandecasteele, Katrien},
  issn         = {1083-7159},
  journal      = {ONCOLOGIST},
  keyword      = {Stage III-IV,Debulking,Randomized trials,Ovarian cancer,type 1 and 2,Categories,PRIMARY CYTOREDUCTIVE SURGERY,GYNECOLOGIC-ONCOLOGY-GROUP,ADVANCED-STAGE OVARIAN,NEOADJUVANT CHEMOTHERAPY,SURGICAL CYTOREDUCTION,INDUCTION CHEMOTHERAPY,EXPLORATORY ANALYSIS,PROGNOSTIC-FACTOR,CARCINOMA,SURVIVAL},
  language     = {eng},
  number       = {6},
  pages        = {745--754},
  title        = {Advanced ovarian cancer: primary or interval debulking? : five categories of patients in view of the results of randomize trials and tumor biology : primary debulking surgery an interval debulking surgery for advanced ovarian cancer},
  url          = {http://dx.doi.org/10.1634/theoncologist.2015-0239},
  volume       = {21},
  year         = {2016},
}

Altmetric
View in Altmetric
Web of Science
Times cited: